Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Approves 18 New Products
September 27, 2011
- MHLW Asks Prefectural Authorities for Cooperation to Ensure Stable Supply of Flu Vaccine
September 27, 2011
- MHLW Announces JAN for 8 Drug Candidates
September 26, 2011
- Prime Minister Noda Stresses Need for Comprehensive Reform in First Major Policy Speech
September 26, 2011
- METI Seeks Budget to Collect Cancer Tissues, Genetic Data in Fukushima
September 26, 2011
- Korosho Plans to Apply for PIC/S Membership in Early 2012
September 26, 2011
- Daiichi Sankyo Announces Approval of Silodosin in China; Aims for Launch in 2012
September 26, 2011
- Growth in Prescriptions of Prazaxa May Hit Snag Due to “Blue Letter”
September 26, 2011
- Why Generics’ Market Share Appears So Low in Japan; 20% Actually Means 35.7% if Overseas Calculation Method is Used
September 26, 2011
- 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
- Government Designates Fulvestrant as Ad-restricted Drug
September 21, 2011
- HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
- Price Settlement Rate Down to 73.9% of Sales in June, Close to Pre-emergency Recommendation Levels
September 19, 2011
- New METI Minister Edano Considers Drug Industry as “Highly Promising Area”
September 19, 2011
- FY2011 White Paper Calls For Reform toward “Participatory” Social Security System
September 19, 2011
- PMDA Expresses Distrust of MSD for Deviations from GCP in Trials of Gardasil
September 19, 2011
- Some Medical Institutions Still Demanding Full Payment, No Refund of Clinical Trial Costs
September 19, 2011
- Discussions Continue on Relief System for Victims of ADRs Due to Anticancer Drugs
September 19, 2011
- Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
- Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…